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Abstract
The APOE gene is one of currently only two genes that have consistently been associated with longevity.
Apolipoprotein E (APOE) is a plasma protein which plays an important role in lipid and lipoprotein metabolism. In
humans, there are three major APOE isoforms, designated APOE2, APOE3, and APOE4. Of these three isoforms,
APOE3 is most common while APOE4 was shown to be associated with age-related diseases, including
cardiovascular and Alzheimer’s disease, and therefore an increased mortality risk with advanced age. Evidence
accumulates, showing that oxidative stress and, correspondingly, mitochondrial function is affected in an APOE
isoform-dependent manner. Accordingly, several stress response pathways implicated in the aging process,
including the endoplasmic reticulum stress response and immune function, appear to be influenced by the APOE
genotype. The investigation and development of treatment strategies targeting APOE4 have not resolved any
therapeutic yet that could be entirely recommended. This mini-review provides an overview on the state of
research concerning the impact of the APOE genotype on stress response-related processes, emphasizing the
strong interconnection between mitochondrial function, endoplasmic reticulum stress and the immune response.
Furthermore, this review addresses potential treatment strategies and associated pitfalls as well as lifestyle
interventions that could benefit people with an at risk APOE4 genotype.
Keywords: Apolipoprotein E isoform, Oxidative stress, Endoplasmic reticulum stress, Mitochondrial function,
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Background
General relevance of the topic
Aging is characterized by both a proceeding decline in
biological functions and a decreased stress resistance [1].
This raises the organisms’ susceptibility to disease and is
reflected in an increase in all-cause mortality with
advanced age [2]. Accordingly, aging is defined as the “ac-
cumulation of diverse deleterious changes in cells and tis-
sues with advancing age that increase the risk of disease
and death” [3]. Increasing evidence suggests a certain de-
gree of heritability of lifespan [4–6]. Genetic difference is
assumed to account for approximately 15–25 % of the
variance in human lifespan [7, 8]. So far, candidate gene
(CGAS) and genome-wide association studies (GWAS)
have identified variation in only two genes, namely fork-
head box O3 (FOXO3) and apolipoprotein E (APOE) to be
consistently associated with human longevity [8–14]. Of
these two loci, APOE was the first to be identified [9]. Not
surprisingly, APOE has since then been extensively stud-
ied in the context of aging [15].
Role of APOE in lipid metabolism
In the 1970s, APOE was discovered as a constituent of
lipoproteins and potent modulator of plasma lipoprotein
and cholesterol concentrations. Up to 75 % of the
plasma APOE is synthesized by liver parenchymal cells
[16]; however, other organs and tissues produce signifi-
cant amounts of APOE, most notably the brain, but also
spleen, kidneys, macrophages and adipocytes [17–19]. In
its primary role as an apolipoprotein, APOE maintains
the structural integrity of lipoproteins and facilitates
their solubilization in the blood [20]. APOE is funda-
mentally involved in the lipid homeostasis of hepatic
and non-hepatic tissues. Both the exogenous and the en-
dogenous pathway of lipoprotein metabolism depend on
APOE. Chylomicrons, synthesized and secreted by the
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intestine to transport dietary lipids to the liver and adi-
pose tissues, acquire APOE in the circulation. Very low
density lipoprotein (VLDL) particles secreted by the liver
comprise APOE and transport endogenously synthesized
triglycerides, phospholipids, and cholesterol and choles-
teryl esters to peripheral tissues [19]. As a high-affinity lig-
and for receptors of the low density lipoprotein (LDL)
receptor family, APOE facilitates the internalization of
lipids into hepatic and extrahepatic cells [21]. Moreover,
APOE produced by macrophages plays a pivotal role in
the so-called reverse cholesterol transport, where excess
cholesterol from peripheral tissues is redirected via
APOE-containing high density lipoprotein (HDL) particles
to the liver for elimination [22, 23]. By these functions,
APOE is fundamentally involved in the lipid and choles-
terol homeostasis. Figure 1 provides the interested reader
with a more extensive overview on the role of APOE in
plasma lipoprotein metabolism.
Additional functions of APOE
Over the course of time, studies on Apoe knockout (KO)
mice and in vitro studies revealed functions of APOE
which can not entirely be attributed to its role in lipid me-
tabolism and strongly suggest APOE to be involved in the
aging process. Apoe KO mice lack endogenous Apoe ex-
pression due to gene targeting-induced inactivation of the
murine Apoe gene [24]. These mice display age-related
phenotypes, including an earlier loss of hair follicles, gray-
ing, arrested spermatogenesis [19] and also a shortened
lifespan [19, 25]. Apoe KO mice show an altered lipopro-
tein profile compared with wild type mice and spontan-
eously develop atherosclerosis [26], which made them a
powerful tool in cardiovascular disease (CVD) research
[20]. Moreover, Apoe KO mice suffer from neurological
disorders [27]; they develop type II diabetes [25] and show
defects in the immune response, leaving them more prone
to bacterial infections [28, 29] and LPS-induced death
[30]. Furthermore, Apoe KO mice showed elevated
markers of oxidative stress [31] and in vitro studies later
substantiated APOE to bear anti-oxidative properties [32].
Although the impact of oxidative stress and damage on
lifespan remains controversial, its influence on the devel-
opment of certain (age-related) pathophysiological condi-
tions is undisputed [33]. Oxidative stress has been shown
to augment APOE secretion from adipocytes and APOE
overexpression protected cells from hydrogen peroxide-
induced damage [34]. By its pleiotropic nature, the APOE
gene affects multiple phenotypic traits simultaneously
depending on the site of APOE protein synthesis. The
multiple functions of the APOE protein make it a potent
modulator of cellular stress response processes and the
aging process.
Fig. 1 Overview on the role of apolipoprotein E (APOE) in the three main pathways of plasma lipoprotein metabolism. In the exogenous
pathway, chylomicrons (CM) are generated in the intestine from dietary fat and cholesterol and enter the systemic circulation, where they acquire
APOE. CM are lipolyzed by lipoprotein lipase (LPL) and form CM remnants (CMR). Peripheral tissues, e.g., skeletal muscle and adipose tissue, take
up released free fatty acids (FFA) and cholesterol. CMR undergo hepatic clearance after APOE-mediated binding to cell surface receptors, e.g., low
density lipoprotein (LDL) receptor (LDLR) or LDLR-related protein (LRP) and heparan sulfate proteoglycan (HSPG) pathways. In the endogenous
pathway, very low density lipoproteins (VLDL) are synthesized and secreted by the liver. LPL and hepatic lipase (HL) cause the release of FFA and
the formation of VLDL remnants which can be cleared by the liver by APOE-mediated uptake (see above). Complete hydrolysis of VLDL results in
the formation of LDL which lack APOE (LDL contain APOB-100 which mediates cellular uptake). The reverse cholesterol transport (RCT) enables ex-
cess cholesterol to be redirected from peripheral tissues to the liver via high density lipoproteins (HDL) that comprise APOE. APOE apolipoprotein
E, CM chylomicron, CMR CM remnant, FFA free fatty acids, HDL high density lipoprotein, HL hepatic lipase, HSPG heparan sulfate proteoglycan, IDL
intermediate density lipoprotein, LDL low density lipoprotein, LDLR LDL receptor, LPL lipoprotein lipase, LRP LDL receptor-related protein, RCT re-
verse cholesterol transport. Figure prepared according to [22, 23, 176]
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APOE structure and polymorphism
The human APOE gene is located on the long arm of
chromosome 19, in close proximity to the genes of apo-
lipoprotein C-I and C-II. The low density lipoprotein re-
ceptor (LDLR) is located on the short arm of the same
chromosome, suggesting chromosome 19 to play an im-
portant role in lipoprotein metabolism [35]. The APOE
gene is composed of four exons, separated by three in-
trons [36]. The mature APOE protein found in plasma is
299 amino acids long (Molecular weight ~34000 Dal-
ton). However, the primary translated APOE gene prod-
uct comprises 317 amino acids with an N-terminal 18
amino acids long signaling peptide being removed co-
translationally. Prior to secretion, the APOE protein
undergoes O-linked glycosylation and sialylation in the
Golgi apparatus; but most plasma APOE is post-
secretory de-sialylated [37]. The exon 4 of the APOE
gene also inherits the two non-synonymous single nu-
cleotide polymorphisms, which gave rise to the three
major APOE alleles ε2, ε3, and ε4 (rs429358C>T: distin-
guishes ε3 and ε4, rs7412C>T: distinguishes ε3 and ε2).
These alleles encode six major APOE genotypes (three
homozygous and three heterozygous). Basis of the APOE
protein isoforms are single amino acid interchanges at
positions 112 and 158 (APOE3 has cysteine on residue
112 and arginine at residue 158, while APOE2 carries
cysteine and APOE4 arginine on both positions; [38,
39]). Worldwide, allelic variation in the APOE locus
ranges from 0 to 20 % for ε2, 60-90 % for ε3, and 10–
20 % for ε4 alleles, respectively [40].
The amino acid interchanges influence both the struc-
ture and the function of the resulting isoproteins. Lipid-
free APOE consists of two independently folded do-
mains, which are separated by a hinge region. The N-
terminal LDL-receptor binding domain is arranged in a
four-helix bundle. The major C-terminal domain con-
tains amphipathic α-helices, which mediate the high-
affinity binding of APOE to lipoproteins [39, 41]. APOE
isoforms show different lipoprotein binding preferences.
While APOE3 and APOE2 preferentially bind high dens-
ity lipoprotein (HDL), APOE4 rather associates with
VLDL particles [42]. The enhanced association of
APOE4 with VLDL is likely a consequence of the greater
lipid-binding ability based on the protein structure, with
the stability of the APOE protein or its readiness to un-
fold appearing to be the determining factor [43]. It has
been shown that the molecular stability of the APOE
isoproteins decreases in the order APOE2>APOE3>A-
POE4 [43]. Next to a decreased stability, APOE4 tends
to form a molten globule state [44]. It had been sug-
gested that in APOE4 a unique interaction occurs be-
tween the N- and C-terminal domain which is not as
pronounced in APOE3 and APOE2. More precisely, a
salt bridge formation between the amino acid residues
Arg61 (N-terminal domain) and Glu255 (C-terminal do-
main) (for a visual depiction of these proposed struc-
tures of APOE3 and APOE4 see [39]) was suggested to
be responsible for the direction of the lipoprotein prefer-
ence of APOE4 towards VLDL. This interaction was re-
ferred to as APOE4 domain interaction [41, 42, 45].
Later, the NMR structure of full-length APOE3 revealed
several interactions between the two domains to also
occur in APOE3 [41, 46]. Mizuguchi et al. [47] reported a
greater stabilizing effect of the C-terminal domain on the
N-terminal domain in APOE3 compared with APOE4.
Instead of a direct interaction of the C- and N-terminal
domain in APOE4, Frieden and Garai [41] suggested that
the positive charge of arginine at position 112 in the
APOE4 protein is propagated to the C-terminal domain
resulting in structural changes. This view is substantiated
by recent computational simulations which indeed
showed more contacts between the N- and C- terminal
domain in APOE4, but with Arg61 and Glu255 appearing
rather noninvolved [48]. Overall, both the N-terminal and
C-terminal domain appear to be less stable in APOE4 and
the reduced stability of the two domains is likely influen-
cing its lipoprotein-binding abilities [49]. The APOE iso-
forms also differ in their LDL receptor binding affinities.
While APOE3 and APOE4 bind to the LDL receptor with
similar affinity, APOE2 appears defective in its receptor
binding ability, displaying only about 1 % of the binding
ability of APOE3 and APOE4 [50]. Both the specific lipo-
protein binding preferences and the differential LDL re-
ceptor binding affinities contribute to the modulation of
plasma lipid levels in response to variation in the APOE
gene. Interestingly, APOE isoforms confer different dis-
ease susceptibilities. APOE2 is associated with increased
plasma levels of cholesterol and triglycerides, which makes
it a risk factor for type III hyperlipoproteinemia [50].
APOE4 is associated with an increased risk for cardiovas-
cular disease (CVD), generally attributed to the higher
plasma triglyceride and LDL cholesterol concentrations
observed in APOE ε4 carriers [20]. More obvious, the ε4
allele increases the risk and decreases the age of onset of
late-onset Alzheimer’s disease (AD) in a dose-dependent
manner [51]. Not unexpectedly, the frequency of APOE ε4
carriers decreases with age [52]. Therefore, Gerdes et al.
[53] suggest entitling APOE a “frailty gene” rather than re-
ferring to it as a determinant of longevity.
Main text
APOE genotype and cellular stress response - linking
APOE to the aging process
Increasing evidence links the APOE genotype to the cel-
lular stress response and to the aging process. Overall,
APOE4 appears rather defective in its response to
stressors as it will be discussed below.
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APOE genotype and response to oxidative stress
Shortly after studies on Apoe KO mice had revealed an-
tioxidative properties of APOE [31], in vitro studies indi-
cated isoform-specific antioxidative properties in the
order APOE2>APOE3>APOE4 [32]. Later, this was at-
tributed to the number of free –SH groups available in
the respective APOE isoproteins [54]. Since then, a huge
number of studies has demonstrated an association be-
tween the APOE genotype and oxidative stress (reviewed
in [55]). Consistent with being a poorer antioxidant
compared with APOE3 and APOE2, APOE4 was also
less effective in protecting cells from oxidative toxicity
and death both in vitro [32, 56] and in vivo [57]. Accord-
ingly, oxidative stress was elevated in APOE4 vs. APOE3
expressing macrophages [58]. Compared with the rela-
tive unambiguous in vitro situation, in vivo data con-
cerning the association of the APOE genotype with
oxidative stress appears rather inconsistent. While some
reports show that APOE4 is positively associated with
markers of oxidative stress (elevated levels of lipid per-
oxides in APOE ε4/ε3 heterozygous individuals; [59]),
other studies report no significant differences between
the two APOE isoforms (similar levels of F2-isoprostane
and thiobarbituric acid-reactive substances in APOE3
and APOE4 targeted replacement (TR) mice; [60]). It ap-
peared that detrimental effects of APOE4, at least con-
cerning CVD risk, may depend on the co-occurrence of
additional stimuli [55], like tobacco smoke [61, 62] or el-
evated plasma cholesterol [63]. However, according to a
recent meta-analysis on the association of the APOE
genotype and coronary heart disease (CHD) risk, there is
no clear evidence of smoking being in fact a modifier of
the APOE genotype/CHD risk-association [64]. Studies
on the influence of the APOE genotype on antioxidant
enzyme activities in APOE TR mice and brains of AD
patients yielded conflicting results [57, 58, 65]. Nrf2-
dependent gene expression, however, appeared to be di-
minished in presence of APOE4 [66], and likewise levels
of the anti-oxidative and anti-inflammatory metallothio-
neins were lower in various tissues of APOE4 vs. APOE3
TR mice [67]. Interestingly, APOE has also been shown
to induce serum paraoxonase 1 (PON1) activity [68],
and lower PON1 levels were observed in presence of
APOE4 [69]. However, whether this difference in PON1
levels is reflected in a differential interaction of the
APOE isoforms with PON1 remains ambiguous. One
study reported PON1 to bind to both APOE3- and
APOE4-HDL with similar activity and both complexes
inhibited LDL oxidation to a similar extent [68].
Association of the APOE genotype with the ER stress
response and mitochondrial function
Besides the differential association of the APOE isoforms
with oxidative stress and the potential APOE genotype-
dependent regulation of antioxidant defense mecha-
nisms, increasing evidence suggests the APOE genotype
to influence mitochondrial and endoplasmic reticulum
(ER) stress-related processes in an APOE isoform-
specific manner. Mitochondrial dysfunction and distur-
bances in the ubiquitin proteasome system which both
may evoke by oxidative stress are considered hallmarks
of the aging process. Both systems have been implicated
in the pathogenesis of various age-related diseases, par-
ticularly neurodegenerative disorders, such as AD and
Parkinson’s disease [70]. The ER and mitochondria are
interconnected both structurally and functionally [71].
Structurally, they interact via mitochondria-associated
ER membranes (MAM), with mitofusin 2 (MFN2) func-
tioning as a direct anchoring protein. One important
way of communication between the two organelles is
Ca2+ exchange via the calcium transfer channels voltage-
dependent anion channel 1 (VDAC1) and inositol 1,4,5-
triphosphate receptor Ca2+ channel (IP3R), located on
both the mitochondrial and ER site of the MAM [71,
72]. Therefore, ER dysfunction may easily pass on to
mitochondria and vice versa. The two organelles both
significantly contribute to the endogenous production of
reactive oxygen species (ROS) [73].
The ER mediates the synthesis, posttranslational modi-
fication and folding of almost all secretory and mem-
brane proteins and is in these processes highly
dependent on intra-compartmental calcium levels, an
oxidative environment and the availability of specialized
proteins, so-called chaperones, which facilitate proper
protein folding. Changes in ER calcium levels, redox
state but also metabolic or inflammatory changes may
either lead to compromised ER function or an increased
demand for (folded) proteins. Exceedance of the ER fold-
ing capacity causes an accumulation of unfolded or
misfolded proteins in the ER lumen, referred to as ER
stress [73]. In turn, the cell activates the so-called un-
folded protein response (UPR) to restore homeostasis by
inhibiting translation in general but simultaneously acti-
vating UPR target gene transcription. The UPR is based
on ER stress sensing by three ER transmembrane pro-
teins, serine/threonine-protein kinase/endoribonuclease
(IRE1ɑ), eukaryotic translation initiation factor 2-alpha
kinase 3 (PERK), and activating transcription factor 6
(ATF6), which each activates specific downstream signal-
ing cascades when released from the chaperone 78 kDa
glucose-regulated protein (GRP78; functioning as a lu-
minal inhibitor). IRE1ɑ activates splicing of various
mRNAs in the cytoplasm, including the mRNA of X-box
binding protein 1 (XBP1), which is thereby activated to
XBP1(S). PERK, by inhibition of the translation initiating
factor eukaryotic translation initiation factor 2A (EIF2A),
promotes general translation inhibition while favoring
activating transcription factor 4 (ATF4) transcription.
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ATF6 is cleaved by proteolysis upon activation. The
cytoplasmic fraction of ATF6 (ATF6 p50), XBP1(S), and
ATF4 translocate into the nucleus and induce transcrip-
tional activation of UPR target genes, including GRP78.
Prolonged activation of the UPR may lead to cell death
by transcriptional induction of the pro-apoptotic factor
DNA damage-inducible transcript 3 protein (DDIT3)
[71]. Interestingly, all three pathways of the UPR can
trigger inflammatory processes by activating NF-kB [74].
It has been hypothesized that APOE4, due to its struc-
tural characteristics, might be recognized by the ER as
misfolded, subsequently leading to the activation of the
ER stress response [75]. Furthermore, the different fold-
ing status of APOE4 was shown to affect its trafficking
through the secretory pathway [76]. Table 1 provides an
overview of studies with relevant findings concerning
the association of the APOE genotype with ER stress.
Interestingly, there is evidence to suggest that ER stress
is indeed an early feature of APOE4 pathogenicity.
APOE4 compared with APOE3 TR mice showed en-
hanced phosphorylation of EIF2A in the brain as early as
4 months of age and already displayed mild cognitive
impairment [77]. Moreover, Zhong et al. [75] reported
all three pathways of the UPR up-regulated in primary
Arg61 APOE mouse astrocytes. In these mice the threo-
nine at position 61, present in the APOE amino acid se-
quence of all mammals despite humans and rabbits
(which carry arginine at this position), is replaced by ar-
ginine. In consequence, these mice display APOE4 do-
main interaction [75], which was hypothesized to be a
characteristic feature of the APOE4 protein [42, 45], as
it has been already stated earlier. Furthermore, intracel-
lular trafficking of APOE4 has been shown to be im-
paired in transfected murine Neuro-2a cells and primary
neurons of APOE transgenic mice. However, this ap-
peared not to be accompanied by elevated ER stress.
Interestingly, normal trafficking of APOE4 was restored
by either treating APOE4 with small-molecule structure
correctors, which shall convey the structure of APOE4
into an APOE3-like state or by the introduction of
threonine at position 61 [76]. Data on the association of
the APOE genotype with ER stress in tissues other than
the brain is rather limited. Two studies on the influence
of the APOE genotype on ER stress parameters in
peritoneal macrophages report conflicting results. Eberlé
et al. [78] found ER stress unaffected by APOE4 domain
interaction in resident peritoneal macrophages of Arg61
APOE mice, though cellular dysfunction in terms of
Table 1 Selected studies on APOE and endoplasmic reticulum stress
Reference Model system ER stress-relevant findings in E4-carrying cells
Sabaretnam et al.
[80]
APOE4 vs. APOE3 transfected HepG2 cells - Trafficking velocity ↓
Zhong et al. [75] Primary astrocytes from Arg-61 APOE mice vs. wild type mice
astrocytes
- Intracellular APOE concentration↓
- Levels and fragmentation of Oasis ↑
- Levels of UPR components and
downstream effectors (ATF4, XBP1, BIP,
GRP94, PDI, GADD34, Herp, CHOP) ↑
Brodbeck et al. [76] EGFP-APOE4 vs. EGFP-APOE3 transfected Neuro-2a
cells and primary murine hippocampal neurons
- Retention of APOE in Golgi and ER ↑
- Trafficking of APOE in the Golgi/Soma ↓
- PERK, ATF6, XBP1, IRE1ɑ, CHOP, BIP protein levels ↔
Impaired EGFP-APOE4 trafficking rescued by R61T
mutation or APOE4 structure correctors.
Eberlé et al. [78] Primary peritoneal macrophages from Arg-61
APOE vs. Thr-61 APOE mice
- APOE secretion ↓
- ATF4, CHOP, TRB3 mRNA levels ↔
Cash et al. [79] Primary peritoneal macrophages from APOE4
vs. APOE3 TR mice
- Inflammation-induced apoptosis ↑
- Efferocytosis ↓
- Basal and stimulated conditions:
JNK phosphorylation ↑
- Stimulated conditions:
IRE1ɑ, PERK phosphorylation ↑
XBP1(S), CHOP mRNA and protein levels ↑
Improved efferocytosis, reduced apoptosis after
tauroursodeoxycholic acid treatment.
Simpson et al. [81] Human astrocyte transcriptome (lateral temporal
cortex; APOE ε4 carriers vs. non-carriers)
Altered pathways incl. transcription (ATF4, FOXN3)
and ubiquitin-mediated proteolysis (ATG7, UBA5)
Segev et al. [77] APOE4 vs. APOE3 TR mice (age: 4 months, cortex and hippocampus) - Phosphorylation of eIF2ɑ, GCN2, PKR ↑
ATF4 activating transcription factor 4, ATF6 activating transcription factor 6, ATG7 autophagy related 7, APOE apolipoprotein E, BIP binding immunoglobulin protein,
CHOP c/EBP-homologous protein 10, EGFP enhanced green fluorescent protein, ER endoplasmic reticulum, FOXN3 forkhead box N3, GADD34 protein phosphatase 1,
regulatory subunit 15A, GCN eukaryotic translation initiation factor 2 alpha kinase 4, GRP94 heat shock protein 90, beta, HERP homocysteine-inducible, endoplasmic
reticulum stress-inducible, ubiquitin-like domain member 1, IRE1α serine/threonine-protein kinase/endoribonuclease, JNK mitogen-activated protein kinase 8, OASIS old
astrocyte specifically induced substance, PDI protein disulfide isomerase associated 3, PERK eukaryotic translation initiation factor 2-alpha kinase 3, PKR eukaryotic
translation initiation factor 2-alpha kinase 2, TRB3 tribbles homolog 3, UBA5 ubiquitin like modifier activating enzyme 5, XBP1 X-box binding protein 1
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reduced APOE secretion was observed. However, hypo-
morphic mutant mice used in the study secrete low
amounts of APOE which might have impacted the
results [79]. By contrast, peritoneal macrophages of
APOE4 TR mice showed reduced phagocytic clearance
of dead cells and elevated apoptosis sensitivity. These ef-
fects were ameliorated by treatment of the cells with the
ER chaperone tauroursodeoxycholic acid [79]. A reduced
trafficking velocity of APOE4 has also been observed in
transfected human liver cells [80]. Human astrocyte
transcriptome data substantiated an APOE genotype-
dependent differential expression of markers of ER stress
(e.g., ATF4) [81].
One way through which protein homeostasis may be
impaired is oxidative damage which has been shown to be
often tightly linked to mitochondrial dysfunction [70].
The primary role of mitochondria is energy production in
form of adenosine triphosphate (ATP) via oxidative phos-
phorylation (OXPHOS). During this process, ROS are
continuously generated as by-products. Additional func-
tions of mitochondria include the regulation of metabolite
levels, metal metabolism and Ca2+ homeostasis, processes
that depend on proper OXPHOS function [82].
In situations of increased ATP demands, mitochon-
drial mass is increased by mitochondrial biogenesis. The
key players in this process are peroxisome proliferator-
activated receptors (PPARs), PPAR co-activators (e.g.,
PGC-1ɑ) and nuclear respiratory factors (NRFs), which
are induced by the energy sensors adenosine monopho-
sphate (AMP)-activated protein kinase (AMPK) and
sirtuin 1 (SIRT1). Architecture and function of mito-
chondria are tightly linked and depend on the coordi-
nated actions of fission- (including dynamin 1-like
protein 1, DNM1L or DRP1; fission 1, mitochondrial,
FIS1) and fusion- (including mitofusins, MFN1/2; optic
atrophy 1 protein, OPA1) promoting proteins. Fission
and fusion enable exchange of proteins and mitochon-
drial DNA between mitochondria and the production of
proper sized organelles [82, 83]. Mitochondria are also
involved in apoptosis and thereby in determining cell
fate under stress conditions. Ca2+ overload and/or oxida-
tive stress initiate steps of the apoptotic cascade, includ-
ing cytochrome c release by mitochondria. This is
usually based on the coordinated action of the pro- and
anti-apoptotic proteins of the B cell lymphoma 2 family
members (BCL2), opening of the mitochondrial per-
meability transition pore and organelle fragmentation
[84, 85]. Damaged mitochondria are degraded through a
mitochondria-specific autophagy-related pathway re-
ferred to as mitophagy. Importantly, evidence supports
the hypothesis that defects in mitochondrial function,
including OXPHOS deficiency, in one tissue may be sig-
naled to the whole organism by mechanisms that are
not yet entirely understood [82].
Due to the strong association of APOE ε4 with AD,
much of the data concerning mitochondrial function in
relation to the APOE genotype was obtained in models
of AD. Mitochondrial dysfunction has been reported to
occur early in the pathogenesis of AD [86] and also ap-
pears to be an early sign of APOE4 pathogenicity [87].
Positron-emission tomography (PET) studies revealed
abnormally low glucose metabolism in brains of APOE
ε4 carriers with [88–90] and without [91–95] diagnosed
AD, detectable already at relatively young ages
(<40 years) [96]. In the brain, glucose is the primary sub-
strate for OXPHOS; thus, the brain depends on proper
glucose metabolism [97]. Cell culture experiments re-
vealed specifically APOE4 synthesized by neurons as be-
ing more prone to proteolytic cleavage compared with
APOE3 [98–100]. Interestingly, zinc potently induced
APOE4 proteolytic degradation in vitro [101] and, cor-
respondingly, higher levels of zinc were detected previ-
ously in the serum of AD patients carrying the ε4 allele
[101, 102]. Specifically, APOE4 proteolytic fragmentation
led to increased generation of neurotoxic C-terminally
truncated fragments, particularly the fragment APOE (1-
272) [98, 99]. Consistent with this finding, overexpres-
sion of APOE affected mitochondrial function in neu-
rons in an isoform-dependent manner (mitochondrial
dysfunction APOE4>APOE3) [99, 103]. The APOE4 (1-
272) fragment appears to directly interact with mito-
chondria through binding to components of mitochon-
drial complexes III and IV, which resulted in decreased
activities of the two respiratory complexes [103, 104].
More recently, decreased expression levels of respiratory
complexes and a lowered respiratory capacity were also
detected in murine neurons expressing full-length
APOE4 (1-299) [87]. In the same study, astrocytes did
not show any APOE genotype-specific effects, substanti-
ating detrimental effects of APOE4 to be rather neuron-
specific [87]. Down-regulated mitochondrial respiratory
complexes in response to APOE4 have also been ob-
served in gene expression profiling data of post mortem
human hippocampus [105]. James et al. [106] performed
a proteomic analysis of hippocampus-derived mitochon-
dria of APOE3 and APOE4 transgenic mice under basal
conditions and in response to an ischemic challenge.
They found the proteomic signature of mitochondria be-
tween APOE3 and APOE4 mice to be already different
under basal conditions and indicative for a differential
regulation of energy production, metabolism and oxida-
tive stress [106]. More recently, similar results were
reported for synaptosomes of APOE transgenic mice
[107]. Pathways of energy production, particularly of oxi-
dative phosphorylation and ATP synthesis, were down-
regulated in synaptic mitochondria of APOE4 vs. APOE3
transgenic mice [107]. In contrast, Liraz et al. [108] ob-
served higher protein expression levels of the translocase
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of the outer mitochondrial membrane (Tomm40) and
cytochrome c oxidase I (complex IV; mt-Co1 or CIV,
resp.) in young APOE4 vs. APOE3 TR mice; however,
this may represent a compensatory response to the
stress induced by APOE4, as the authors discuss [108].
Consistent with an impaired respiratory function in
presence of APOE4, we observed lower ATP levels in
the brain of APOE4 vs. APOE3 TR mice in our previous
studies [109]. Interestingly, a 3-months dietary curcumin
supplementation induced mitochondrial biogenesis and
expression of mitochondrial respiratory complexes only
in APOE3 but not in APOE4 TR mice, suggesting a
certain unresponsiveness of APOE ε4 to improvements
of mitochondrial function by dietary interventions, at
least as far as curcumin is concerned [109]. In contrast,
supplementation of acetyl-L-carnitine and lipoic acid,
the latter one being the coenzyme of mitochondrial
pyruvate dehydrogenase and α-ketoglutarate dehydro-
genase, led to cognitive improvements in APOE4 TR
mice [110]. It should be noted that both acetyl-L-
carnitine and lipoic acid are also synthesized endogen-
ously; thus responsiveness of APOE ε4 to dietary factors
may depend on the origin of the substances. Further-
more, differential modulation of mitochondrial functions
seems to depend on the cell types investigated; an obser-
vation that may not be limited to the brain but may also
be applicable to other organs and tissues. Table 2
provides an overview of studies with relevant findings
concerning the association of the APOE genotype with
mitochondrial function.
An association between the APOE genotype and mito-
chondrial function is further substantiated by linkage
disequilibrium (LD) structure analysis of the APOE gene
and its neighboring regions which revealed high LD
Table 2 Selected studies in which the effect of the APOE genotype on mitochondrial function-related traits was investigated. Only
studies were included in which effects of APOE4 were compared with those of APOE3
Reference Model system Main findings; APOE4 vs. APOE3
Mosconi et al. [88, 89]; Langbaum et al. [90];
Small et al. [91, 93]; Reiman et al. [92, 94–96]
Human subjects with and without diagnosed
AD (brain)
-Glucose hypometabolism
Xu et al. [105] Hippocampi of human APOE ε3/ε3 and
APOE ε4/ε4 AD patients
-Mitochondrial oxidative phosphorylation
and energy metabolism ↓
Turchan-Cholewo et al. [173] Human neuronal cultures -GSH concentrations and mitochondrial
membrane potential after treatment with
HIV protein and opiate ↓
No effect in astrocytes.
Valla et al. [174] Young APOE ε4 carriers and non-carriers
(posterior cingulate cortex tissue)
-CIV activity ↓
Chen et al. [87] Primary neurons from NSE-APOE transgenic
mice (cortex)
Primary astrocytes from GFAP-APOE transgenic
mice (cortex)
Neuro-2A cells stably expressing APOE3 and
APOE4, resp.
-Protein levels CI-V ↓
-Protein levels CI-V ↔
-Protein levels CI, CIV and CV ↓
-mRNA expression CIV subunit 1, CV subunit α ↓,
Vdac1 ↑
-Activity CIV↓, citrate synthase ↔
-Mitochondrial respiratory capacity ↓
APOE4-R61T mutation or GIND24 treatment
abolished detrimental effects on mitochondria.
James et al. [106] Mitochondrial fractions (hippocampus) from
APOE transgenic mice
-Differential regulation of TCA cycle,
ETC and ATP synthesis
Liraz et al. [108] Young APOE TR mice
(4 months old, hippocampal neurons)
-Protein expression Tomm40, CIV subunit 1 ↓
Chin et al. [109] Old APOE TR mice
(15 months old, cortex)
-ATP levels ↓
-mRNA expression Ppargc1a, Gabpa ↓
Shi et al. [107] Mitochondrial fractions (synaptosomes)
from GFAP-APOE transgenic mice
-Pathways TCA, ETC, oxidation reduction ↓
-ATP synthesis ↓
-GSSG, MDA ↑
Effect stronger in presence of female gender.
No effect in non-synaptic mitochondria.
Tambini et al. [175] Human fibroblasts treated with
astrocyte-conditioned media
obtained from APOE4 and
APOE3 TR mice, resp.
-MAM activity ↑
APOE apolipoprotein E, ATP adenosine triphosphate, CI-V complexes I-V of the mitochondrial respiratory chain, ETC electron transport chain, Gabpa GA-binding
protein alpha chain, GSH glutathione, GSSG glutathione disulfide, HIV human immunodeficiency virus, MAM mitochondria-associated endoplasmic reticulum (ER)
membranes, MDA malondialdehyde, Ppargc1a, peroxisome proliferator-activated receptor gamma, coactivator 1 alpha, TCA tricarboxylic acid, Tomm40 translocase
of the outer mitochondrial membrane
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levels between three SNPs in the TOMM40 gene and the
APOE ε4 allele [111].
APOE genotype and the inflammatory response
As stated earlier, all three pathways of the UPR may trig-
ger the inflammatory response by activating the pro-
inflammatory transcription factor NF-kB [74]. Further-
more, oxidative stress and mitochondrial dysfunction are
implicated in the inflammatory immune response. Sub-
stances released by damaged mitochondria promote in-
flammation. Eventually, the heightened inflammatory
response in turn worsens ER stress and mitochondrial
dysfunction [112]. Noteworthy, one characteristic of the
aging process is the induction of low-grade chronic in-
flammation, often referred to as inflammaging, which is
believed to be involved in the pathogenesis of several
age-related chronic diseases, including AD and CVD
[113]. An increasing number of evidence supports an
APOE isoform-dependent modulation of the inflamma-
tory response, with APOE4 appearing to be more associ-
ated with an overactive pro-inflammatory response to
diverse stimuli (reviewed in [55]). In a number of stud-
ies, APOE4 has been shown to be less effective in down-
regulating the activation of microglia and peripheral
macrophages and suppressing the release of pro-
inflammatory cytokines and other inflammatory media-
tors both in vitro and in vivo [114–118]. On the con-
trary, two studies reported lower levels of pro-
inflammatory cytokines in APOE4 vs. APOE3 expressing
astrocytes [119] and Schwann cells (the principal glia
cells in the CNS) [120]. The authors discuss this as a
sign of APOE4-dysfunctionality in the production of cy-
tokines to combat inflammation [119, 120]. Strikingly, in
co-culture systems of microglia expressing the APOE
isoforms and neurons, neurotoxicity was shown to be
greatest with APOE4 expressing microglia [114].
Activated-like morphology of microglia in presence of
APOE4 has already been observed in un-stimulated
cells, potentially pointing towards a pro-inflammatory
phenotype as an inherited property of APOE4 expressing
cells [115]. Accordingly, in brains of AD patients, signifi-
cantly more activated and scattered microglia were ob-
served in carriers of the ε4 allele [121]. The main
signaling transduction pathways involved in the direc-
tion of the APOE isoform-specific inflammatory re-
sponses include the NF-kB and the mitogen-activated
protein kinase MAPK (p38 MAPK and JNK) pathways
[114, 119, 122]. Very recent evidence indicates that
APOE4 not only enhances pro-inflammatory pathways,
but may also impact on the inflammatory response via
the suppression of anti-inflammatory pathways. While
NF-kB activation and the subsequent prostaglandin E2
(PGE2)-pathway were significantly up-regulated in pri-
mary microglia of APOE4 vs. APOE3 TR mice, the
expression of the anti-inflammatory TREM2 (triggering
receptor expressed on myeloid cells 2) was suppressed
in presence of APOE4 [123]. However, it should be
noted that, though the heightened inflammatory re-
sponse in presence of APOE ε4 may be deleterious to
the organism with advanced age, it may confer greater
protection from pathogens early in life (“antagonistic
pleiotropy” theory, [124]). Indeed, a still quite high
prevalence of APOE ε4 is still observed in certain indi-
genous populations, including Pygmies, Khoisan, and ab-
origines of Malaysia and Australia, where APOE ε4
frequency ranges from 24 to 40.7 % [125]. Interestingly,
spontaneous abortions [126] and still-births [127] were
found to be less frequent in APOE ε4 allele carriers, sug-
gesting that APOE4 somehow protects the developing
embryo [126, 127]. Furthermore, Oriá et al. [128] re-
ported positive effects of APOE ε4 on the cognitive and
physical development in children who suffered from
heavy diarrhea in early childhood in a slum region in
Brazil, where malnutrition is common [128–130]. More-
over, APOE ε4 appeared beneficial in certain infectious
diseases evoked by both viruses (e.g., hepatitis C, HCV)
and bacteria (e.g., malaria) [131–133], though, on the
contrary seemed rather detrimental in the case of hu-
man immunodeficiency virus (HIV) and herpes simplex
virus (HSV) infections [134, 135] (reviewed in [136]).
Therapeutic approaches targeting APOE4
Nowadays, several companies offer genetic testing to the
public and provide their customers with information
about ancestry, disease susceptibility genes, and about
effects of dietary habits, drug use and other environmen-
tal factors on the individuals’ health. Websites offering
information and support for people genotyped positive
for certain gene variants arise quickly. The APOE gene is
gaining more and more public attention. The role of
APOE4 as a mortality factor in the elderly is undisputed.
Because of the magnitude of impact of APOE4 on vari-
ous age-related diseases and the relatively high fre-
quency of the ε4 allele in the population, prevention
strategies targeting APOE4 gain in importance, particu-
larly in view of the ongoing “population aging” [137].
Several approaches come into consideration, including
pharmacoprevention strategies, dietary and lifestyle in-
terventions, as well as gene editing.
Pharmacoprevention
APOE inducers
One target of interest in pharmacoprevention research is
the discovery of drugs that raise APOE levels. APOE ε4
carriers have been shown to display lower APOE levels
in blood [138–141] and brain tissue [141–144]. Interest-
ingly, the ε2 allele, whose carriers seem more likely to
reach centenarian age, is associated with the highest
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blood APOE levels among the APOE isoforms [145].
Few candidate drugs that induce APOE production have
been identified so far. The non-steroidal anti-
inflammatory drugs indomethacin and aspirin induced
APOE levels in rat microglia and astrocyte cell cultures
via an unknown mechanism [146]. Probucol, a
cholesterol-lowering drug, induced APOE and low dens-
ity lipoprotein receptor-related protein (LRP) in the
hippocampus of aged rats [147]. Agonists of the liver X
receptor (LXR) and retinoid X receptor (RXR) may also
be promising candidates. Both have been shown to in-
duce APOE production on the transcript level [145, 148,
149]. Furthermore, 17ß-estradiol elevated APOE protein
levels in mice [150]. Indeed, some detrimental effects of
APOE4 have been shown preventable by the administra-
tion of APOE-inducers. Bexarotene for example, an RXR
agonist, raised hope, when Cramer et al. [149] reported
it to enhance amyloid beta (Aß)-clearance and to restore
cognitive deficits in a mouse model of AD, though, since
then, increasing evidence queries the effectiveness of
bexarotene in preventing AD characteristic features
[151, 152]. The increase in APOE levels induced by pro-
bucol was shown to improve Alzheimer’s Disease As-
sessment Scale-Cognitive subscale (ADAS-Cog) scores
and to inversely correlate with phosphorylated tau in the
cerebrospinal fluid (CSF), a marker of neuronal damage
in AD subjects [145]. Next to APOE-inducing agents,
APOE mimetic peptides are under investigation for the
treatment of pathological changes in the central nervous
system, and potentially these peptides can eventually
also be administered to compensate APOE4 functional
deficits [153, 154]. It should be noted that opposing evi-
dence exists, suggesting that reducing rather than in-
creasing APOE expression might be the more preferable
approach, at least as far as the lowering of brain Aβ
levels is concerned [155]. The reassessment of drugs
which are already on the market for other purposes
might be a promising strategy to discover new treatment
opportunities for detrimental health outcomes associated
with the ε4 allele.
Small-molecule structure correctors
Another pharmacotherapeutic approach, though still in
its infancy, is the search for so-called small-molecule
structure correctors, i.e., substances that induce correct
APOE4 folding to restore proper protein function [137].
As mentioned previously, it was proposed that APOE4 is
structurally different from APOE3 and APOE2 in a way
that allows an interaction between the amino- and
carboxyl-terminal domain [45]. Whether this interaction
is based on a salt bridge between two amino acid resi-
dues or is rather attributable to allosteric effects remains
to be clarified [47], as stated earlier. In addition to this
so-called “domain interaction”, APOE4 has been shown
to assume the form of a molten globule [44]. Re-
searchers from the Gladstone Institute in San Francisco,
US, who established a screening platform for putative
structure correctors, are forefront in the discovery of
substances able to convert APOE4 into an APOE3-like
conformation. Readouts cover both APOE4 intramolecu-
lar interaction (or the disruption thereof; fluorescence
resonance energy transfer (FRET) assay) and diverse as-
says to measure functional effects, mainly involving cell
culture systems [137]. Few compounds with high po-
tency (nanomolar range) as putative APOE4 structure
correctors, mainly phthalazinone analogs, have been
identified so far and have proved effectiveness in vitro.
Treatment of APOE4 with these substances restored mt-
CO1 (CIV) expression and mitochondrial motility, and
promoted neurite outgrowth in cultured neurons [156].
Earlier identified substances with lower potency (milli-
molar range) had already been shown to restore normal
trafficking in the endoplasmic reticulum and Golgi ap-
paratus [76] and to decrease Aß-production [157] in
vitro. However, structure correctors identified so far
have caused toxicity in mice. A pyrazoline analogue
identified more recently may eventually hold some
promise [156].
Dietary and lifestyle strategies
Pharmacoprevention may be the most effective strategy
to ameliorate detrimental outcomes associated with
APOE4; however, the discovery of new drugs is time-
consuming and cost-intensive. Furthermore, drug dis-
covery trials often come to nothing, when safety con-
cerns are encountered. Therefore, alternative strategies
become more and more important, including dietary
and lifestyle interventions [145]. Studies investigating
the effects of dietary fat manipulation on blood lipid
levels in relation to the APOE genotype yielded incon-
sistent results. However, APOE variation may influence
the effects of fish oil supplementation on blood LDL
levels. In a group of individuals with an atherogenic lipo-
protein phenotype, APOE ε4 carriers showed a greater
raise in LDL cholesterol levels after fish oil supplementa-
tion (eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), 3 g/d) compared with carriers of the other
APOE isoforms [158], though the effect may be highly
dose-dependent [159]. As aforementioned, APOE ε4 ap-
peared rather insensitive to other dietary interventions.
Quercetin supplementation, for example, exerted benefi-
cial effects (blood pressure and plasma tumor necrosis
factor alpha (TNF-α) reduction) only in presence of
APOE ε3, but not APOE ε4 in humans and APOE TR
mice [160, 161]. Similarly, curcumin supplementation
raised ATP levels only in APOE3, but not in APOE4
mice [109]. However, supplementation of acetyl-L-
carnitine and lipoic acid was shown to improve cognitive
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functions in APOE4 TR mice [110], as stated earlier.
APOE ε4 carriers may have a slightly increased demand
for dietary vitamin E, since vitamin E uptake into extra-
hepatic tissues was shown to be reduced and vitamin E
degradation enhanced in APOE4 compared with APOE3
mice [162–164]. On the other hand, APOE ε4 carriers
were shown to exhibit higher intestinal absorption of
dietary vitamin D and calcium [165]. APOE ε4 carriers
can also benefit from increasing their physical activity. It
was shown that physical activity reduced the risk of
CVD and protected cognitive functions especially in car-
riers of the ε4 allele [166, 167]. However, success of life-
style interventions depends on the collaboration of the
people concerned, what ultimately questions real-life-
applicability [145].
Genome editing
New therapeutic possibilities may arise from the use of
‘genome editing’, i.e., the direct manipulation of the
DNA sequence. Initial methods aiming at a conversion
of APOE ε4 into APOE ε3 were based on homologous
recombination [36]. First in vitro approaches using hy-
brid RNA-DNA oligonucleotides, so-called chimera-
plasts, were shown to cause cytotoxic side-effects [168].
Improved methods using shorter single-stranded all-
DNA oligonucleotides have appeared more promising so
far [36]. Substantial progress in the field of gene editing
in general was made by the use of specific nucleases that
can cleave the DNA at nearly every desired position in-
cluding ZFNs (zinc-finger nucleases), TALENs (transcrip-
tion activator-like effector nucleases) and the CRISPR/
Cas9 (Clustered Regularly Interspaced Short Palindromic
Repeats/Cas9 nuclease) system [169]. It remains to be
established whether these tools will eventually be used to
target the genomic sequence of APOE ε4 [36].
Conclusion and outlook
Taken together, the current review highlights the impact
of the APOE genotype on the modulation of stress re-
sponse processes. However, the findings reviewed within
this work support tissue-specific pathological patterns of
APOE4. In the light of the pleiotropic nature of the
APOE protein, therapeutic interventions targeting
APOE4 should be chosen carefully not to abolish benefi-
cial features of APOE4. As mentioned earlier, APOE4
may be beneficial early in life when infectious diseases
are of greater importance to health than chronic disor-
ders. This may especially apply to populations under
high infectious pressure and a high prevalence of malnu-
trition. Furthermore, we previously reported associations
of APOE ε4 with higher levels of both vitamin D [165]
and adiponectin [170]. Strikingly, there is also evidence
for APOE ε4 being protective in age-related macular
degeneration, a classical age-related disease [171].
Nevertheless, in industrialized countries, APOE4 is asso-
ciated with premature death. Although the mechanisms
by which APOE4 exerts its pathologic effects remain
largely unknown, a recent study showing nuclear trans-
location and direct transcriptional activity of APOE4
with binding sites in promoter regions of as many as
1700 genes (among others, genes involved in neuron
nourishment, cell death and aging) [172] opens up new
possibilities on the mode of action of APOE4. This
knowledge may potentially help targeting and treating
effects of APOE4 more specifically.
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